NCT06070051View on ClinicalTrials.gov

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

VRON-0200-AdC6

VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

BIOLOGICAL

VRON-0200-AdC7

VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection

Trial Locations (3)

Unknown

Chinese University of Hong Kong, Hong Kong

Aotearoa Clinical Trials, Middlemore Hospital, Auckland

Auckland City Hospital, Auckland

Sponsors
All Listed Sponsors
collaborator

Vir Biotechnology, Inc.

INDUSTRY

lead

Virion Therapeutics

INDUSTRY

NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy | Biotech Hunter | Biotech Hunter